Daily Ards Research Analysis
Analyzed 10 papers and selected 3 impactful papers.
Summary
Longitudinal metabolomics in critically ill patients identified time-varying metabolic response patterns that stratify hospital-acquired pneumonia and ARDS risk and may predict response to interferon gamma-1b. A 3-year prospective cohort of COVID-19 ALI/ARDS survivors shows persistent PASC linked to frailty but not to sustained inflammation, endothelial dysfunction, or complement activation. A sepsis-ARDS mortality nomogram integrating immune-inflammatory-nutritional markers outperformed SOFA with strong internal validation.
Research Themes
- Metabolomics-driven risk stratification and treatment response in critical illness
- Long-term outcomes and mechanisms after COVID-19 ALI/ARDS
- Biomarker-integrated prognostication for sepsis-associated ARDS
Selected Articles
1. Identification of a robust metabolic signature associated with hospital-acquired pneumonia and response to interferon-gamma treatment in critically ill patients.
Longitudinal blood metabolomics in brain-injured ICU patients revealed three metabolic response patterns, driven by fatty acid metabolism, that stratify HAP and ARDS risk. Patterns replicated in an independent RCT dataset and differentially associated with likelihood of benefit from interferon gamma-1b, suggesting a precision immunotherapy approach.
Impact: Integrating temporal metabolomics with replication across cohorts offers a robust, mechanistically anchored stratification of infection and ARDS risk with potential to guide targeted immunomodulation.
Clinical Implications: Early metabolic profiling could identify ICU patients at high risk for HAP/ARDS and those more likely to benefit from interferon gamma-1b, enabling targeted prophylaxis or therapy pending prospective validation.
Key Findings
- Three longitudinal metabolic response patterns were identified, primarily involving fatty acid metabolism, with graded risks of HAP (24%, 60%, 78%) and ARDS (6%, 16%, 43%).
- Patterns and their temporal metabolite trajectories replicated in an independent dataset from the PREV-HAP RCT (HAP rates 18%, 28%, 40%).
- Interferon gamma-1b was associated with decreased probability of ICU discharge alive in low-risk patterns and increased probability in high-risk patterns, indicating potential predictive enrichment.
Methodological Strengths
- Prospective longitudinal sampling with unsupervised consensus clustering across multiple time points.
- Independent replication using an RCT-derived dataset with a simple Fast-and-Frugal Tree classifier.
Limitations
- Moderate sample size and focus on brain-injured ICU patients may limit generalizability.
- Observational design precludes causal inference; interferon gamma-1b findings are exploratory.
Future Directions: Prospective interventional trials stratified by metabolic response patterns to test interferon gamma-1b (or alternative immunomodulators) and external validation across broader ICU populations.
AIM: Our objective was to increase our understanding of the effects of the time course of metabolic alterations on the risk of hospital-acquired pneumonia (HAP) and response to treatment in critically ill patients. METHODS: We first studied the blood metabolome at day 1, day 3-4 and day 6-7 of patients from a prospective, observational cohort of brain-injured patients in two French centres. We classified the metabolic response by unsupervised longitudinal consensus clustering. To evaluate the robustness of metabolic patterns, a Fast-and-Frugal Tree trained on the discovery cohort was applied to a replication dataset from the PREV-HAP randomised clinical trial testing interferon gamma-1b for the prevention of HAP in critically ill patients. The primary outcome was the association of metabolic response patterns with HAP. FINDINGS: Of the 128 patients analysed (330 samples), 57 (45%) had developed HAP and 21 (16%) acute respiratory distress syndrome (ARDS).
2. A risk prediction model based on immune-inflammatory-nutritional indicators for predicting 28-day mortality in sepsis patients with acute respiratory distress syndrome.
A seven-variable nomogram using immune-inflammatory-nutritional indices achieved high discrimination for 28-day mortality in sepsis-associated ARDS, outperforming SOFA in both training and validation sets. Calibration and decision curve analyses support clinical utility for individualized risk stratification.
Impact: Provides a pragmatic, readily implementable prognostic tool built from accessible laboratory indices, with performance gains over a widely used benchmark.
Clinical Implications: At ICU admission, clinicians could apply the nomogram to identify high-risk sepsis-ARDS patients for early escalation, resource allocation, or trial enrollment, pending external validation.
Key Findings
- Seven independent predictors (AAPR, ALBI, NLR, PLR, PNI, SII, LAR) formed a nomogram for 28-day mortality in sepsis-ARDS.
- Discrimination: AUC 0.873 (training) and 0.837 (validation), outperforming SOFA (0.689/0.684).
- Good calibration and positive net benefit across ~10–70% thresholds on decision curve analysis support clinical utility.
Methodological Strengths
- Internal validation with strong discrimination and calibration.
- Decision curve analysis demonstrating net clinical benefit; uses readily available lab markers.
Limitations
- Single-center retrospective design; lacks external validation and may risk overfitting.
- Potential residual confounding and sepsis-ARDS heterogeneity not fully addressed.
Future Directions: External, multicenter validation; head-to-head comparisons with machine learning models; impact analyses to test whether nomogram-guided care improves outcomes.
BACKGROUND: Sepsis is a life-threatening condition often complicated by organ dysfunction and is associated with a high mortality rate. The dysregulation of immune response, inflammation, and nutritional status are critical factors contributing to its pathogenesis. This study aimed to develop a nomogram that integrates prognostic immune-inflammatory-nutritional indicators with other clinical information to predict 28-day mortality in sepsis patients with acute respiratory distress syndrome (ARDS). METHODS: Clinical data from 635 adult sepsis patients with ARDS were obtained from Shaanxi Provincial People's Hospital and randomly divided into a training set ( RESULTS: The independent predictors utilized for the construction of the nomogram included the albumin-alkaline phosphatase ratio (AAPR), albumin-bilirubin grade (ALBI), neutrophil-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), prognostic nutritional index (PNI), systemic immune-inflammation index (SII), and lactate-albumin ratio (LAR). Notably, the nomogram exhibited superior predictive performance, with an AUC of 0.873 in the training set and 0.837 in the validation set, as compared to the SOFA score, which showed an AUC of 0.689 in the training set and 0.684 in the validation set, for predicting 28-day mortality in sepsis patients with ARDS. The calibration plots demonstrated excellent consistency. DCA confirmed the model's clinical utility, showing a positive net benefit across a wide range of clinically relevant threshold probabilities (approximately 10% to 70%), which supports its potential to guide clinical decision-making. CONCLUSION: We have successfully developed and validated a robust nomogram that integrates seven readily accessible immune-inflammatory-nutritional indicators. This model serves as an individualized and precise tool for predicting the 28-day mortality risk in sepsis patients with acute respiratory distress syndrome (ARDS), thereby potentially enhancing early risk stratification and informing clinical decision-making.
3. Post-Acute Sequelae of COVID-19 Persist Over 3 Years in Acute Lung Injury/Acute Respiratory Distress Syndrome Survivors But Are Not Associated With Persistent Thromboinflammation or Endothelial Dysfunction.
In 150 severe/critical COVID-19 ALI/ARDS survivors, PASC persisted in 26% at 15 months and 3 years and correlated with frailty and impaired physical performance. Longitudinally measured inflammatory, endothelial, and complement biomarkers were not associated with PASC, arguing against persistent thromboinflammation as a driver.
Impact: Provides multi-year evidence decoupling PASC from sustained systemic inflammation and endothelial dysfunction, refocusing mechanistic and interventional efforts.
Clinical Implications: Routine anti-inflammatory or anticomplement strategies targeting persistent biomarkers may be unwarranted for PASC after COVID-19 ALI/ARDS; emphasis should shift to frailty assessment and rehabilitation.
Key Findings
- PASC prevalence was 26% at both 15 months and 3 years post-hospitalization among severe/critical COVID-19 ALI/ARDS survivors.
- PASC and symptom phenotypes (post-exertional malaise, fatigue, brain fog) were associated with higher frailty category, worse SPPB scores, and shorter 6-minute walk distance.
- Inflammatory (e.g., IL-6, sTNFR-1), endothelial (angiopoietin), and complement (C2, C4b, C5) biomarkers showed no association with PASC in cross-sectional or longitudinal analyses.
Methodological Strengths
- Prospective cohort with 3-year follow-up and serial biomarker measurements at multiple time points.
- Use of standardized RECOVER PASC definition and multivariable adjustment; enriched sampling for mechanically ventilated survivors.
Limitations
- Single-center design with first-wave COVID-19 survivors may limit generalizability to later variants and care eras.
- Panel limited to selected inflammatory/endothelial/complement markers; lacked broader multiomic profiling.
Future Directions: Integrate multiomics (proteomics, metabolomics, epigenomics) with deep phenotyping to uncover non-inflammatory drivers of PASC and target rehabilitation-responsive pathways.
IMPORTANCE: Inflammation, endothelial dysfunction, and complement activation are associated with COVID-19 acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). OBJECTIVES: We hypothesized that higher levels of inflammation, endothelial dysfunction, and complement activation implicated in more severe COVID-19 ALI/ARDS are associated with post-acute sequelae of COVID-19 (PASC) phenotypes in the 3 years after hospitalization. DESIGN, SETTING, AND PARTICIPANTS: A single-center prospective cohort of 150 adult survivors of severe and critical COVID-19 from the first wave of the pandemic with sampling weighted to include 50% survivors of mechanical ventilation. MAIN OUTCOMES AND MEASURES: Eleven serum biomarkers at hospital discharge, 4 months, 15 months, and 3 years, and symptoms and physical function at 15 months and 3 years. PASC presence was defined using the 12 symptoms and scoring from the Researching COVID to Enhance Recovery (RECOVER) definition. We tested associations of biomarkers with PASC and symptom phenotypes of post-exertional malaise, fatigue, and brain fog while adjusting for age, sex, body mass index, comorbidities, and days since COVID-19 diagnosis.